Orphazyme AS (CHIX:ORPHAC) Total Liabilities : kr15.38 Mil (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Total Liabilities?

Orphazyme AS's Total Liabilities for the quarter that ended in Jun. 2022 was kr15.38 Mil.

Orphazyme AS's quarterly Total Liabilities declined from Jun. 2021 (kr261.27 Mil) to Dec. 2021 (kr163.89 Mil) and declined from Dec. 2021 (kr163.89 Mil) to Jun. 2022 (kr15.38 Mil).

Orphazyme AS's annual Total Liabilities increased from Dec. 2019 (kr127.79 Mil) to Dec. 2020 (kr201.97 Mil) but then declined from Dec. 2020 (kr201.97 Mil) to Dec. 2021 (kr163.89 Mil).

Orphazyme AS Total Liabilities Historical Data

The historical data trend for Orphazyme AS's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Total Liabilities Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Liabilities

Get a 7-Day Free Trial

47.12

53.10

127.79

201.97

163.89

Orphazyme AS Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Total Liabilities	Get a 7-Day Free Trial									170.23	201.97	261.27	163.89	15.38

Orphazyme AS Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Orphazyme AS's Total Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	129.092	+	(6.407	+	28.293
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0.098)
	=	163.89

Total Liabilities	=	Total Assets (A: Dec. 2021 )	-	Total Equity (A: Dec. 2021 )
	=	173.229	-	9.339
	=	163.89

Orphazyme AS's Total Liabilities for the quarter that ended in Jun. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	15.384	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	15.38

Total Liabilities	=	Total Assets (Q: Jun. 2022 )	-	Total Equity (Q: Jun. 2022 )
	=	93.589	-	78.205
	=	15.38

Orphazyme AS Total Liabilities Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS (CHIX:ORPHAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines